.png)
Consumers who purchased, paid for or reimbursed the cost of a drug containing metformin in the United States between July 20, 2015, and June 2, 2020, may be eligible to claim a cash payment from class action settlements.
Teva Pharmaceuticals USA Inc., Teva Pharmaceutical Industries Ltd., Actavis Pharma Inc., Actavis LLC, Granules USA Inc., Granules Pharmaceuticals Inc. and Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals Inc.) agreed to pay a total of $5.55 million to resolve class action lawsuits alleging they falsely advertised their generic Metformin drugs as equivalent to Glucophage and/or Glucophage XR despite the drugs allegedly containing N-Nitrosodimethylamine, also known as NDMA, and not meeting U.S. Food and Drug Administration standards. This settlement also resolves claims against CVS Pharmacy Inc. related to its alleged sale of these drugs.
Who can file a claim?
Individuals and entities may be eligible to participate in the settlement if they meet all of the following criteria:
- They are located in the United States, its territories or possessions.
- They paid any amount of money for a metformin-containing drug (for personal or household use) that Teva, Granules or Heritage manufactured, distributed or sold between July 20, 2015, and June 2, 2020.
- Third-party payers (such as health plans) must have paid or reimbursed some or all of the purchase price for a metformin-containing drug.
There are two main groups of eligible claimants:
- Individuals who paid for metformin-containing drugs for personal or household use
- Entities (such as health plans or insurers) that paid or reimbursed metformin-containing drugs during the class period
Who is excluded from the class?
- The settling defendants (Teva, Granules and Heritage) and their subsidiaries and affiliates
- Federal governmental entities
- State and local governmental entities that can only make claims under applicable state law by the state attorney general or are otherwise prohibited from private counsel asserting on a contingent fee basis
- Anyone who purchased metformin-containing drugs for resale
- Anyone who purchased metformin-containing drugs directly from the settling defendants or their affiliates
- Fully insured health plans (plans that purchased insurance from another third-party payer that covered 100% of the plan’s reimbursement obligation for its members)
- Pharmaceutical benefit managers
- Anyone who properly excludes themselves from the class
How much can class members get?
The settlement administrator will distribute the $5.55 million settlement fund to eligible claimants after deducting certain expenses, such as taxes, notice and administration costs, attorneys’ fees and service awards.
The administrator will distribute the payments to class members on a pro rata basis, depending on:
- The amount of metformin-containing drugs the claimant purchased or paid for
- The total number of valid claims submitted
- The total amount of expenses, attorneys’ fees and service awards
The actual amount each claimant receives will depend on the total number of valid claims and the total amount claimed.
- Consumers: Payment is based on the number of prescriptions and total out-of-pocket payments for metformin-containing drugs purchased during the class period
- Third-party payers: Payment is based on the total amount paid or reimbursed for metformin-containing drugs during the class period
If there are leftover funds after the administrator pays all claims, it will distribute them to a nonprofit organization the court approves. The defendants will not receive any funds.
How to claim a class action payment
Class members can submit the online claim form or download, print and complete the PDF claim form and mail it to the settlement administrator.
Settlement administrator's mailing address: In re Metformin Marketing and Sales Practices Litigation, c/o A.B. Data Ltd., P.O. Box 173012, Milwaukee, WI 53217
The claim deadline is July 10, 2026.
What proof or documentation is required to submit a claim?
Claimants must provide documentation to support their claim. Acceptable forms of proof include:
- Pharmacy or insurer records showing purchase of generic metformin-containing drugs
- A note from a doctor or medical records describing the amount of generic metformin prescribed
- Explanation of benefits from a health plan or insurer
- Other records, such as receipts, checkbook entries or credit card statements, showing purchase of metformin-containing drugs between July 20, 2015, and June 2, 2020
Class members who would like a receipt for their mailed claim should send it via certified mail with a return receipt requested.
The settlement does not specify payment methods.
$5.55 million settlement fund breakdown
The $5,550,000 settlement fund covers:
- Notice and administration costs: Up to $500,000
- Attorneys' fees and fees: Up to $1,887,000
- Service awards to class representatives: Up to $3,500 each for eight class representatives ($28,000 total)
- Payments to eligible class members: Remainder of the fund
Important dates
- Deadline to file a claim: July 10, 2026
- Deadline for exclusion: July 10, 2026
- Fairness hearing: Aug. 12, 2026
When is the metformin settlement payout date?
The settlement administrator will issue payment to eligible class members after the court resolves any appeals and grants final approval to the settlement.
Why is there a class action settlement?
The class action lawsuit alleged the defendants falsely advertised their generic metformin drugs as being the same as Glucophage and/or Glucophage XR when they were allegedly contaminated with NDMA and did not meet FDA standards. The plaintiffs claimed that as a result, consumers and third-party payers paid for drugs they would not have otherwise purchased.
The defendants deny any wrongdoing but agreed to settle to avoid the costs and risks of further litigation. The settlement does not cover personal injury or wrongful death claims.
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.svg)